HC Wainwright & Co. Maintains Buy on Vir Biotechnology, Raises Price Target to $22
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsPrice Target
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Vir Biotechnology (NASDAQ:VIR) with a Buy and raises the price target from $20 to $22.
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Vir Biotechnology (NASDAQ:VIR) with a Buy and raises the price target from $20 to $22.